Baseline demographics in overall IMvigor210 cohort before PSM (n=207). Data were analyzed by χ2 test and Wilcoxon test
| Variables | FGFR3-mutated (n=39) | FGFR3-wildtype (n=168) | P value |
| Sex, n (%) | 0.113 | ||
| Female | 12 (30.8) | 30 (17.9) | |
| Male | 27 (69.2) | 138 (82.1) | |
| Race, n (%) | 0.788 | ||
| Non-white | 3 (7.7) | 18 (10.7) | |
| White | 36 (92.3) | 150 (89.3) | |
| Intravesical BCG use, n (%) | 0.002 | ||
| No | 23 (59.0) | 139 (82.7) | |
| Yes | 16 (41.0) | 29 (17.3) | |
| Platinum-based chemotherapy use history, n (%) | 0.903 | ||
| No | 9 (23.1) | 43 (25.6) | |
| Yes | 30 (76.9) | 125 (74.4) | |
| Metastatic site, n (%) | 0.042 | ||
| Lymph node only | 3 (7.7) | 35 (20.8) | |
| Liver | 9 (23.1) | 52 (31.0) | |
| Visceral* | 27 (69.2) | 81 (48.2) | |
| Baseline ECOG score, n (%) | 0.659 | ||
| 0 | 17 (43.6) | 66 (39.3) | |
| 1 | 21 (53.8) | 92 (54.8) | |
| 2 | 1 (2.6) | 10 (6.0) | |
| Tobacco, n (%) | 0.579 | ||
| Never | 14 (35.9) | 50 (29.8) | |
| Ever | 25 (64.1) | 118 (70.2) | |
| Tissue sampling site for sequencing, n (%) | 0.453 | ||
| Primary tumor tissue† | 36 (92.3) | 145 (86.3) | |
| Metasite tumor tissue‡ | 3 (7.7) | 23 (13.7) | |
| PD-L1 tumor infiltrating IC level, n (%) | 0.009 | ||
| IC0 | 15 (38.5) | 35 (20.8) | |
| IC1 | 17 (43.6) | 62 (36.9) | |
| IC2+ | 7 (17.9) | 71 (42.3) | |
| TMB (mut/MB), median (IQR) | 7.2 (5.0–11.3) | 7.7 (4.5–13.5) | 0.472 |
| TMB group, n (%) | 0.299 | ||
| High (≥10) | 11 (28.2) | 65 (38.7) | |
| Low (<10) | 28 (71.8) | 103 (61.3) |
*Visceral metastasis was defined as lung, bone, or any non-lymph node or soft tissue metastasis.
†Primary tumor tissue was from bladder, kidney, or ureter.
‡Metasite tumor tissue was from liver, lung, lymph node or other metastatic sites.
ECOG, Eastern Cooperative Oncology Group; FGFR3, fibroblast growth factor receptor 3 ; IC, immune cell; PD-L1, programmed death ligand 1; PSM, propensity score matched; TMB, tumor mutation burden.